Adjuvant systemic treatment of melanoma;Adjuvante systemische Therapie des Melanoms

Hautarzt

Volumn 62, Issue 6, 2011, Pages 414-422

  Kahler K C ^a   Egberts, F ^a   Hauschild, A ^a   Mohr, P ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Elbekliniken Buxtehude   (Germany)

Author keywords

IFN ; Immunotherapy; Ipilimumab; Malignant melanoma; Vaccine therapy

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; MELANOMA ANTIGEN 3; PEGINTERFERON;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER RISK; DRUG APPROVAL; MELANOMA; METASTASIS; OVERALL SURVIVAL; PROGNOSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 79960222740     PISSN: 00178470     EISSN: 14321173     Source Type: Journal    
DOI: 10.1007/s00105-010-2040-6     Document Type: Article

References (37)

1. Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206
2. Hill GJ, Moss SE, Golomb FM et al (1981) DTIC and combination therapy for melanoma, III: DTIC surgical adjuvant study COG protocol 7040. Cancer 47:2556-2562 (Pubitemid 11113717)
3. Karg C, Garbe C, Orfanos CE (1990) Chemotherapie des malignen Melanoms -aktueller Stand. Hautarzt 41:56-65 (Pubitemid 20066121)
4. Veronesi U, Adamus J, Aubert C (1982) A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 307:913-916 (Pubitemid 12011039)
5. Garbe C, Radny P, Linse R et al (2008) Adjuvant low-dose interferon alpha-2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 19:1195-1201. Epub 2008 Feb 14 (Pubitemid 351796347)
6. Czarnetzki BM, Macher E, Suciu S et al (1993) Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomized multicenter study (EORTC protocol 18781). Eur J Cancer 29A:1237-1242 (Pubitemid 23169888)
7. Kleeberg UR, Suciu S, Brocker EB et al (2004) Final results of the EORTC 18871/DKG 80-1 randomized phase III trial: rIFN-α2b versus rIFN-γ versus ISCADOR M® versus observation after surgery in melanoma patients with either high-risk primary (thickness>3 mm) or regional lymph node metastasis. Eur J Cancer 40:390-402 (Pubitemid 38121277)
8. Hauschild A, Weichenthal M, Balda BR et al (2003) Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol 21:2883-2888 (Pubitemid 46621837)
9. Beiteke U, Ruppert P, Garbe C et al (1993) Adjuvante Therapie des primären malignen Melanoms mit natürlichem humanen Interferon-beta. Signifikanter Überlebensvorteil bei 96 behandelten Patienten im Vergleich zu 288 unbehandelten Symptomenzwillingen. Hautarzt 44:365-371 (Pubitemid 23172165)
10. Stadler R, Luger T, Bieber T et al (2006) Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial. Acta Oncol 45:389-399 (Pubitemid 43884606)
11. Gogas H, Ioannovich J, Dafni U et al (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709-718 (Pubitemid 43247141)
12. Bouwhuis M, Suciu S, Kruit W et al (2007) Prognostic value of autoantibodies (auto-AB) in melanoma patients in the EORTC 18952 trial of adjuvant interferon (IFN) compared to observation. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 suppl):8507
13. Bouwhuis MG, Suciu S, Testori A et al (2010) Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies-EORTC 18991. J Clin Oncol 28:2460-2466
14. Garbe C, Schadendorf D, Stolz W et al (2008) Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges 6 (suppl 1):S9-S14
15. Cameron DA, Cornbleet MC, MacKie RM et al (2001) Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer 84:1146-1149 (Pubitemid 32511329)
16. Grob JJ, Dreno B, de la Salmoniere P et al (1998) Randomized trial of interferon alpha-2b as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 351:1905-1910 (Pubitemid 28297445)
17. Pehamberger H, Soyer HP, Steiner A et al (1998) Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 16:1425-1429 (Pubitemid 28175761)
18. Hauschild A, Weichenthal M, Rass K et al (2010) Efficacy of low-dose interferon alpha-2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol 28:841-846
19. Hauschild A, Weichenthal M, Rass K et al (2009) Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. J Clin Oncol 27:3496-3502
20. Kirkwood JM, Strawderman MH, Ernstorff MS et al (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma. The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17 (Pubitemid 26019991)
21. Kirkwood JM, Ibrahim JG, Sondak VK et al (2000) High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E 1690. J Clin Oncol 18:2444-2458 (Pubitemid 30415832)
22. Kirkwood JM, Ibrahim JG, Sosman JA et al (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIb-III melanoma: results of intergroup trial E 1694. J Clin Oncol 19:2370-2380 (Pubitemid 32391207)
23. Mohr P, Hauschild A, Enk A et al (2008) Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: An interim analysis of a randomized phase III study (NCT00226408). J Clin Oncol 26, (May 20 suppl; abstr 9040)
24. Mohr P, Hauschild A, Rass K et al (2009) Quality-of-life (QoL) impairment in melanoma patients receiving high-dose interferon alpha 2b (IFNa2b). J Clin Oncol 27, (suppl; abstr e20011)
25. Pectasides D, Dafni U, Bafaloukos D et al (2009) Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol 27(6):939-944
26. Cascinelli N, Belli F, MacKie RM et al (2001) Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomized trial. Lancet 358:866-869 (Pubitemid 32900567)
27. Hancock BW, Wheatley K, Harris S et al (2004) Adjuvant interferon in high-risk melanoma: the AIM HIGH Study - United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 22:53-61 (Pubitemid 41095114)
28. Eggermont AM, Suciu S, MacKie R et al (2005) Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomized controlled trial. Lancet 366:1189-1196 (Pubitemid 41393597)
29. Lens MB, Dawes M (2002) Interferon alfa therapy for malignant melanoma: a syste-matic review of randomized controlled trials. J Clin Oncol 20:1818-1825 (Pubitemid 34273271)
30. Wheatley K, Ives N, Hancock B et al (2003) Does adjuvant interferon alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomized trials. Cancer Treat Res 29:241-252 (Pubitemid 37069655)
31. Wheatley K, Ives N, Eggermont A et al (2007) Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. J Clin Oncol ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement):8526
32. Mocellin S, Pasquali S, Rossi CR, Nitti D (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102:493-501
33. Grob JJ, Jouary T, Dreno B et al (2010) Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macro-metastatic nodes: EADO trial. J Clin Oncol 28:18s, (suppl; abstr LBA8506)
34. Eggermont AMM, Suciu S, Santinami M et al (2008) Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372(9633):117-126 (Pubitemid 351952257)
35. Moschos SJ, Edington HD, Land SR et al (2006) Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24:3164-3171 (Pubitemid 46638955)
36. Eggermont AM, Suciu S, Rutkowski P et al (2010) Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: Final results of study EORTC 18961. J Clin Oncol 28:15s, (suppl; abstr 8505)
37. Morton DL, Mozzillo N, Thompson JF et al (2007) An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 25:18S Abstract-Nr. 8508